Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BREC-AGC: Customized Treatment Based on BRCA1 in Advanced Gastric Cancer
NCT01206218Phase 3Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Oct 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of docetaxel in gastric cancer (GC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
docetaxel
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT01206218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01206218.